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Obstrução coronária pós-TAVI 
In patients considered inoperable or at high risk for surgical aor-
tic valve replacement, transcatheter aortic valve replacement (TAVR) 
has been established as the treatment of choice.1
Coronary obstruction following TAVR, while uncommon, is an 
acute life-threatening complication. The incidence of this cata-
strophic complication is described as less than 1% in most of the cur-
rent registries.2,3 The acute and late mortality rate post-coronary 
obstruction is very high. After successful percutaneous coronary 
intervention (PCI), it is 22%, and after successful coronary artery by-
pass surgery, 50%, while unsuccessful PCI correlates with 100% mor-
tality. Overall, the 30-day mortality approaches 40%.3
Clinical presentation includes severe profound refractory hypo-
tension or immediate cardiac arrest, electrocardiographic changes 
such as ST elevation, ST depression, and ventricular arrhythmias 
with hemodynamic collapse, as well as segmental wall motion ab-
normalities shown echocardiographically. Unfortunately, the sole 
presence of hypotension without electrocardiographic changes is 
also not unusual. The fact that on some occasions the coronary flow 
is not completely obstructed may explain the less dramatic initial 
presentations. 
It has been shown that coronary obstruction after TAVR is, in most 
of the cases, related to displacement of a bulky calcified native leaflet 
towards/over a coronary ostium during valve implantation.4 Theoret-
ically, the complication can be also the consequence of a high valve 
implantation, with the sealing cuff placed against the coronary osti-
um. A dislodged native valve calculus could migrate and occlude a 
coronary artery, even hours after the procedure, as recently reported.5
The risk of coronary obstruction is difficult to assess, since there is 
no single measurement to consider, but rather a constellation of clini-
cal, anatomical, and procedural factors that play a different role in 
each procedure. A recent registry has provided further insight into the 
baseline characteristics, identifying advanced age, female sex, prior 
valve surgery, and higher EuroSCORE as clinical predictors, while 
showing that the use of balloon-expandable valves doubles the risk as 
a procedural factor.3 The fact that self-expanding valve anatomical re-
quirements are much more conservative than balloon expandable 
valve requirements has generated a selection bias that may, at least 
partially, explain this difference. However, self-expanding valves pose 
their own unique challenges: it is more difficult to perform coronary 
protection with a guiding catheter trapped behind the metallic struts 
(ascending aorta level) of this valve type. Also, coronary access 
through the metal cage of a self-expanding valve can be particularly 
challenging or impossible. A duplicate implant of a self-expanding 
valve may extend the covered stent strut area to the higher level in a 
particularly unfavorable configuration. 
The major anatomical predictors of coronary obstruction are coro-
nary height, coronary sinus, and aortic root size (Fig 1). Measuring the 
coronary height perpendicular to the annular plane is more conserva-
tive and has been shown to be more reproducible. However, it could 
also be measured from the leaflet insertion to the lower edge of the 
coronary ostia, in an oblique fashion. The left main coronary artery 
(LMCA; 89%) is more commonly affected in comparison to the right 
coronary artery (RCA; 4%), or bilateral obstruction (7%),3 most likely due 
to the generally higher level of RCA ostia take-off. The cut-off for LMCA 
height is < 12 mm (mean of 11 mm), while for RCA it is unknown, given 
the low number of patients reported. A narrow aortic ‘’tube-like’’ root 
together with shallow sinuses of Valsalva is also strongly associated to 
coronary obstruction. The cutoff for the sinuses of Valsalva width is 
< 30 mm. It is paramount to stress that the sinuses of Valsalva measure 
must be taken in relation to the annulus, since the difference between 
them will represent the space where the leaflet will be accommodated 
after valve deployment. A sinuses of Valsalva/annulus ratio under 1.26 ± 
0.04 has been demonstrated to be highly correlated with this complica-
tion (odds ratio = 20; 95% of confidence interval  = 1.28–333).3,6
Other weaker predictors recognized in the computed tomography 
analysis are the degree of valve calcification, the presence of eccentric 
bulky calcific nodules in relation to the coronary ostia, and the leaflet 
length.6 The leaflet length should be measured in an oblique coronal 
view, from the leaflet insertion to the tip of the leaflet. Its absolute 
value is useless unless associated to the coronary height. In fact, it has 
been postulated that the risk of obstruction increases as the ratio 
LMCA ostium height/leaflet length falls below 1/1. 
Only the integration of these factors, together with the pre-pro-
cedural considerations such as a proper valve over/under-sizing, can 
aid in obtaining a reliable and predictable result, often accepting mi-
nor paravalvular leaks in order to avert catastrophic complications 
such as coronary obstruction and annular rupture. 
In these cases, preventive measures should be instituted only if 
the final risk/benefit evaluation after the 3-D imaging screening fa-
vors TAVR over surgical aortic valve replacement/medical treatment.
After identifying a high-risk patient, the interventional team 
must prepare to protect the coronary artery at risk. These patients 
should be treated in a fully equipped hybrid operating room, under 
general anesthesia and with expert 3-D echo guidance.
In uncertain cases, in which computed tomography and 3-D echo 
have poor correlation or the risk is thought to be moderate, an aorto-
gram in left anterior oblique/cranial projection during balloon aortic 
valvuloplasty may simulate the final result after valve deployment.7 
In this issue of the Revista Brasileira de Cardiologia Invasiva, Furi-
ni et al.8 elegantly present “Coronary occlusion after TAVI: safety 
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strategy report.” The authors describe in detail the steps taken in 
order to prevent coronary obstruction in a high-risk case. Of note, 
this group performed an aortogram during balloon aortic valvu-
loplasty to assess coronary patency. This technique is well known 
and appears to be somewhat useful, particularly if it confirms ab-
sent coronary flow with balloon inflation in the valve location. How-
ever, the best subsequent step is not clear in cases with patent 
coronary arteries during balloon inflation.
Several factors may preclude the technique to properly simulate 
the actual valve implantation. First, the aortogram must be per-
formed only when the balloon is fully expanded. Moreover, the bal-
loon’s nominal size should theoretically equal the final outer size of 
the implanted valve. The latter is obviously very difficult to accom-
plish, due to limited balloon size availability and the fact that final 
oversizing or undersizing is not easy to predict, especially in cases 
that require post-dilatation due to para-valvular leak (notably, this 
should be rarely undertaken if a possible coronary obstruction is 
suspected). For safety reasons, there will obviously be a general ten-
dency to use smaller valvuloplasty balloons than needed. 
In this case report, despite no coronary compromise in the aortogram, 
the operators still decided to protect the RCA with a wire and a stent.
It is important to stress the fact that in this frail population, mini-
mizing the use of contrast and valve manipulation could make a differ-
ence in term of contrast induced nephropathy and stroke. Also, balloon 
aortic valvuloplasty alone was responsible for about 10% of the coro-
nary occlusion during TAVR in a recent registry,3 and several groups are 
avoiding the valvuloplasty step prior to TAVR. Thus, wiring the at-risk 
coronary artery could also be considered prior to this maneuver. 
Due to the difficulty in delivering a stent once coronary obstruc-
tion is established, we suggest protecting the coronary at risk with a 
wire and a stent (Fig. 2). As Furini et al.8 described, after document-
ing absence or impaired flow in the coronary artery, pulling the 
stent and deploying it at the ostium would be much easier than try-
ing to advance it against a calcified obstructive leaflet. Also, it is be-
lieved that the stent shaft itself may contribute to avoid the coronary 
occlusion by preventing the valve tissue from displacement over the 
ostia. Therefore, after valve deployment, if no intervention is need-
ed, the stent should be retrieved gently and a re-assessment should 
be done before pulling the coronary wire.
Of note, some groups have started to protect the coronaries 
with a deflated balloon. Unfortunately, in some cases, after ostia 
balloon dilatation, the instant recoil of the “squashed” leaflet be-
tween the valve struts and the coronary ostia precludes the ad-
vancement of the stents. Interestingly, the Mayo Clinic group 
recently described the use of temporary balloon inflation in LMCA 
ostium during valvuloplasty and TAVR in order to avoid coronary 
embolization, after having identified mobile debris in the left coro-
nary cusp by 3-D trans-thoracic echocardiography.9 This must cer-
t a in ly be considered an except ional measure,  dr iven by 
highly-individualized particular measurements of low coronary 
ostium height, narrow sinuses of Valsalva and root diameters, and 
an eccentric unfavorably-situated calcification. 
In order to avoid the need of an extra arterial access for coronary 
protection, one may consider the use of a 6 F guiding catheter with 
side-holes that will replace the pigtail for the aortogram. The econo-
my of arterial access may become critical in the next few years, if the 
ongoing clinical trials favor the use of embolic protection devices 
(which will require a dedicated arterial access site).
After valve deployment, the trained echocardiographer must cer-
tify the appropriate global left ventricular function, the presence of 
laminar flow in the coronary arteries, and the absence of new seg-
mental wall motion abnormalities. The identification of turbulent 
flow together with the previously described clinical scenario will 
confirm the complication on course, and should alert the interven-
tionalist to perform an emergent angioplasty to re-establish the cor-
onary flow.
Since stent compression after deployment is not rare, identifica-
tion of laminar coronary flow using 3-D transesophageal echocardi-
Figure 1. Multidetector computed tomography analysis of the aortic valvar complex. (A) Sinuses of Valsalva dimensions. (B) Left main coronary artery height, measured perpen-
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ography, or evaluation of stent patency by intravascular ultrasound 
or angiography, should be carefully performed after coronary angio-
plasty/stent. Not infrequently, a second stent needs to be deployed 
to achieve enough radial force and improve the minimal lumen area. 
It is important to emphasize that the stent should protrude from the 
true ostium, creating a tunnel through the compressed leaflets to-
wards the aorta. A proximal “flaring” technique to complete the in-
tervention may facilitate a re-intervention if needed in the future. 
The treatment of this complication mandates immediate ac-
tion in order to re-establish coronary perfusion. Even when the 
coronary artery was not previously protected, nearly 80% of pa-
tients can be rescued by successful PCI. However, most of them 
will require hemodynamic support or conversion to open heart 
surgery. In some situations, the rapid initiation of temporary ex-
tracorporeal circulation may be of assistance if coronary bypass 
grafting might solve the problem.
Retrograde left ventricular support devices, such as Impella™ 
were reported to be beneficial in the setting of hemodynamic in-
stability due to coronary obstruction.10 This device has arisen as 
an expeditious alternative to cardiopulmonary bypass for the 
treatment of shock during TAVR, given the already available 
large-bore arterial access. Nevertheless, this option may be limit-
ed by the difficulty of recrossing the newly implanted valve (this 
is especially true if a double self-expanding implant has been 
used); therefore, maintaining wire access in the left ventricle 
during echocardiographic post-TAVR evaluation of possible coro-
nary obstruction may be important. Theoretically, an intraortic 
balloon pump would be of little help if the coronary artery is oc-
cluded, but it may be considered if there is a partial occlusion. 
The decline in catastrophic complications after TAVR could be ex-
plained by the improvement in valve prostheses, the decreasing di-
ameter of the delivery sheaths, the improved imaging methods, and 
the operators’ experience. Furthermore, advances in careful 
pre-procedural screening and planning utilizing 3-D imaging, such 
as multidetector computer tomography and echo, have contributed 
enormously to the identification of high-risk patients.
Awareness of high-risk features for coronary obstruction, pro-
phylactic measures, and prompt recognition and management of 
this complication are paramount for a successful TAVR. A well-es-
tablished and well-functioning heart team composed not only by 
cardiac surgeons and interventional cardiologists, but also by imag-
ing specialists in cardiovascular computed tomography and inter-
ventional echocardiographers and cardiac anesthesiologists, as well 
as a fully trained technician and nurse team, plays a critical role in 
the final outcome of this procedure.
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